The Anderson Perspective

Atea's promising Hep C drug offers a shorter, simpler regimen for complex patients, but faces a tough market. Meanwhile, the firm tackles a neglected virus.

With Visa, Wells Fargo, and Alibaba joining the Agentic AI Foundation, the race is on to build open standards for a future run by autonomous AI.

Meshy 7's new foundation model introduces a rigorous benchmark for accuracy, promising 3D assets that finally match the source image. Is this the end of 'close enough'?

With a $30M Series A, Mindgard is turning a decade of university research into a new defense against AI's unique and complex vulnerabilities.

A new deal between China's RYET and Saudi's Intersect Holding isn't just business. It's a blueprint for building a localized, AI-powered future.

Tencent's latest earnings reveal a shocking negative cash flow, driven by a 176% surge in spending. It's a high-stakes gamble on AI to redefine its future.

For millions with treatment-resistant depression, hope is scarce. A Toronto company is pioneering a non-invasive ultrasound therapy that could change everything.

With promising data for its lead cancer drug and a fortified financial runway, C4 Therapeutics is executing a tangible plan to fight a relentless disease.

A court ruling clears a path for a massive potash mine in the Amazon, promising fertilizer independence for Brazil but igniting fierce opposition from Indigenous groups.

Milwaukee's Central Bark lands on the Inc. 5000 list, revealing how a focus on 'whole dog care' is driving national growth and reshaping the pet industry.

The Ontario lumber producer posts a striking Q2 profit after a deep loss, but the surprise resignation of its CEO raises questions about future stability.

Getty Images faces a liquidity crisis with soaring debt and a failed merger, raising doubts about its future despite some growth in its core business.

Bristol Myers Squibb's massive Texas campus isn't just about jobs. It's a high-tech play to reshore drug manufacturing and revolutionize how we make medicine.

Miami-based Gencom restructures into two distinct units, sharpening its focus on investment and execution to scale its $8 billion luxury real estate empire.

Bota Box's new Napa Valley Cabernet challenges tradition, offering elite wine in sustainable packaging. A look at how value, quality, and eco-consciousness are merging.

A new drug, divesiran, shows stunning success in trials, offering hope to those with a rare blood cancer by potentially replacing frequent phlebotomies with a quarterly shot.

With Jennifer Orlando at the helm, Juice Plus+ signals a new era, but can a new leader reshape a legacy brand in the complex direct selling landscape?

SOLIZE PARTNERS and Dassault Systèmes are betting on a proven model to tackle Japan's manufacturing woes, combining a powerful platform with deep human expertise.

A revamped basketball court offers vital relief to stressed medical students in Nigeria, but the story reveals a complex intersection of corporate goodwill and scrutiny.

A 5% revenue dip masks a surge in users and a high-stakes bet on a new 'Predictions' product. Is DraftKings sacrificing a quarter to win the war?